Insider Trading March 24, 2026

Director Leonard Tannenbaum Increases Stake in Advanced Flower Capital Through $447,389 Buy

Series of purchases between March 20-24, 2026 adds 174,517 shares as company faces recent earnings shortfall and depressed share price

By Jordan Park AFCG
Director Leonard Tannenbaum Increases Stake in Advanced Flower Capital Through $447,389 Buy
AFCG

Advanced Flower Capital Inc. director Leonard Tannenbaum purchased 174,517 shares of the company between March 20 and March 24, 2026, in transactions totaling $447,389. The buys occurred at prices between $2.55 and $2.59 per share. The transactions come as AFCG stock has fallen roughly 54% over the past year and following a fourth-quarter 2025 earnings and revenue miss.

Key Points

  • Director Leonard Tannenbaum bought 174,517 shares of Advanced Flower Capital between March 20 and March 24, 2026, spending $447,389 at prices from $2.55 to $2.59.
  • Tannenbaum now directly owns 6,373,106 shares; his spouse holds 218,907 shares and the Tannenbaum Family Foundation holds 180,400 shares, which he disclaims beneficial ownership of.
  • The purchases coincide with a 54% decline in AFCG's share price over the past year, a Price/Book ratio of 0.35, and the company’s fourth-quarter 2025 earnings and revenue miss.

Leonard Tannenbaum, a director at Advanced Flower Capital Inc., executed a series of open-market purchases of the company's common stock totaling 174,517 shares over a five-day period in late March 2026, according to a Form 4 filing with the Securities and Exchange Commission.

The filings show the acquisitions took place between March 20 and March 24, 2026, at prices that ranged from $2.55 to $2.59 per share, amounting to $447,389 in aggregate consideration. On March 20, Tannenbaum acquired 115,237 shares at a weighted average price of $2.55. He followed with purchases of 14,366 shares on March 23 and 44,914 shares on March 24, both at a weighted average price of $2.59.

Following these transactions, Tannenbaum directly holds 6,373,106 shares of Advanced Flower Capital common stock. The Form 4 also notes that his spouse holds 218,907 shares and the Tannenbaum Family Foundation holds 180,400 shares; Tannenbaum disclaims beneficial ownership of those indirectly held positions.

The insider purchases arrive against a backdrop of recent weakness in the company stock. AFCG shares have declined approximately 54 percent over the last 12 months and currently trade at $2.62, a price noted as being close to the 52-week low of $2.06. The stock is trading at a Price/Book ratio of 0.35. Some analysis cited in relation to the company indicates that the shares may be undervalued at current levels.

Advanced Flower Capital also recently released fourth-quarter 2025 results that missed consensus expectations. The company reported an adjusted loss per share of $0.12 for the quarter, versus a consensus estimate of $0.03, a variance reported as a -500 percent surprise. Revenue for the period came in at $5.19 million, below the anticipated $5.46 million.

Despite the earnings and revenue shortfall, the stock experienced a slight uptick in pre-market trading following the release. As of the filing, analyst firms had not publicly updated ratings or delivered new coverage in response to the quarterly results. Market participants and shareholders will be monitoring any subsequent guidance, strategic commentary, or corporate actions from the company.


Contextual note: The transactions described are disclosed in the company filings and reflect the holdings and purchases reported for Leonard Tannenbaum and related parties as stated above.

Risks

  • Recent fourth-quarter 2025 results missed expectations on both EPS and revenue - this earnings shortfall is a near-term operational and market risk for shareholders.
  • The stock has declined 54% year-over-year and is trading near its 52-week low, indicating potential liquidity or market-confidence concerns that could affect trading volatility.
  • Analyst coverage has not yet been updated following the earnings release, leaving uncertainty around future analyst guidance or rating changes that could influence investor sentiment.

More from Insider Trading

Hinge Health CFO James Budge Sells $465K in Class A Shares Mar 24, 2026 Hinge Health President Disposes of $633,927 in Stock via 10b5-1 Plan Mar 24, 2026 Silver Lake Sells $49.3M of Dell Class C Stock as Conversions, Corporate Upgrades Also Reported Mar 24, 2026 Bristow Director Disposes of 1,000 VTOL Shares in $45,000 Transaction Mar 24, 2026 Serina Therapeutics CSO Sells Shares, Exercises Options as Company Advances Parkinson’s Program Mar 24, 2026